Paik Paul K, Goyal Ravi K, Cai Beilei, Price Mark A, Davis Keith L, Ansquer Valerie Derrien, Caro Nydia, Saliba Teddy R
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Manhattan, NY 10065, USA.
Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA.
Future Oncol. 2023 Jan;19(3):217-228. doi: 10.2217/fon-2022-1133. Epub 2023 Feb 7.
To assess real-world clinical outcomes in patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practice. Patient data were collected using a retrospective medical record review, led by participating oncologists. Eligible patients initiated treatment with capmatinib in any line, after BM diagnosis, between May 2020 and June 2021. Data on real-world overall response rate (rwORR) and real-world progression-free survival (rwPFS) were descriptively analyzed. 68 eligible patients were analyzed. In patients treated with first-line (1L) capmatinib (n = 55), the rwORR was 90.9% systemically and 87.3% intracranially; median systemic rwPFS was 14.1 months. Among radiation-naive patients on 1L capmatinib (n = 20), rwORR was 85.0%, both systemically and intracranially; median systemic rwPFS was 14.1 months. This study showed substantial systemic and intracranial effectiveness for capmatinib in real-world setting; findings were consistent for RT-naive patients.
为评估在接受卡马替尼（一种最近获批的MET抑制剂）治疗的、伴有MET外显子14跳跃突变和脑转移（BM）的非小细胞肺癌患者中的真实世界临床结局，该研究在美国常规临床实践中开展。患者数据通过回顾性病历审查收集，由参与研究的肿瘤学家主导。符合条件的患者在2020年5月至2021年6月期间，于脑转移诊断后开始使用卡马替尼进行任何线治疗。对真实世界总缓解率（rwORR）和真实世界无进展生存期（rwPFS）的数据进行描述性分析。共分析了68例符合条件的患者。在接受一线（1L）卡马替尼治疗的患者（n = 55）中，全身rwORR为90.9%，颅内rwORR为87.3%；全身rwPFS中位数为14.1个月。在接受1L卡马替尼治疗且未接受过放疗的患者（n = 20）中，全身和颅内rwORR均为85.0%；全身rwPFS中位数为14.1个月。本研究表明，在真实世界中，卡马替尼具有显著的全身和颅内有效性；对于未接受过放疗的患者，研究结果一致。
